Skip to main content

Table 3 The assess of association between alpha-lipoic acid supplementation on inflammatory markers based on subgroup analysis

From: The effects of alpha-lipoic acid supplementation on inflammatory markers among patients with metabolic syndrome and related disorders: a systematic review and meta-analysis of randomized controlled trials

Variables

Number of SMD included

Subgroups

Pooled OR (random effect)

95% CI

I2 (%)

overall I2(%)

CRP

Geographic area

6

Asia

−1.20

−2.02, − 0.38

90.8

93.7

5

European

−2.52

−4.26, −0.78

94.8

1

USA

−0.46

− 0.98, 0.07

–

1

Oceania

0.05

−0.41, 0.51

–

Dosage of ALA (mg/day)

4

< 600

−1.29

−2.16, −0.42

81.4

9

≥600

−1.64

−2.61, −0.66

95.4

Type of intervention

9

ALA

−1.63

−2.67, −0.58

95.3

4

ALA plus other nutrients

−1.30

−2.10, −0.50

85.0

Duration of study (week)

10

≥8

−1.50

−2.35, −0.65

94.4

3

< 8

−1.63

−2.93, −0.32

88.6

Type of diseases

3

Diabetic

−1.63

−2.93, −0.32

88.6

10

Other

−1.50

−2.35, −0.65

94.4

IL-6

Geographic area

4

Asia

−2.18

−3.34, −1.02

88.7

90.6

6

European

−1.75

−2.71, −0.78

87.4

3

USA

−4.10

−7.68, −0.52

96.3

1

Oceania

−0.26

−0.72, 0.20

–

1

Africa

−0.57

−1.17, 0.03

–

Dosage of ALA (mg/day)

5

< 600

−3.59

−5.50, −1.68

94.8

10

≥600

−1.22

− 1.70, −0.74

78.4

Type of intervention

8

ALA

−2.00

−2.88, −1.11

90.9

7

ALA plus other nutrients

−1.98

−3.01, −0.95

91.7

Duration of study (week)

8

≥8

−1.07

− 1.62, −0.52

85.1

7

< 8

−3.30

−4.61, −1.99

89.9

Type of diseases

2

Diabetic

−3.40

−5.13, −1.66

75.1

13

Other

−1.72

−2.35, − 1.09

89.5

TNF-α

Geographic area

3

Asia

−2.44

−4.67, −0.21

95.9

94.3

5

European

−2.63

−3.87, −1.39

87.2

1

Oceania

−0.34

− 0.80, 0.12

–

1

Africa

−6.35

−8.16, −4.54

–

Dosage of ALA (mg/day)

1

< 600

−2.14

−2.77, −1.51

–

9

≥600

−2.71

−3.94, − 1.48

94.7

Type of intervention

6

ALA

−2.56

−4.08, −1.03

95.8

4

ALA plus other nutrients

−2.73

−4.26, −1.20

89.3

Duration of study (week)

5

≥8

−2.78

−4.57, −0.99

96.8

5

< 8

−2.40

−3.46, −1.33

80.2

Type of diseases

3

Diabetic

−4.68

−7.82, −1.55

92.8

7

Other

−1.89

−3.04, −0.73

94.0

  1. ESRD end-stage renal disease, IL-6 interlokin-6, CRP C-reactive protein, TNF-α tumor necrosis factor alpha